Who makes ST-246 Days 11 - 13?

ST-246 Days 11 - 13 is developed by SIGA Technologies.

What development phase is ST-246 Days 11 - 13 in?

ST-246 Days 11 - 13 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

ST-246 Days 11 - 13

SIGA Technologies · Phase 1 active Small molecule

At a glance

Generic name	ST-246 Days 11 - 13
Also known as	Tecovirimat
Sponsor	SIGA Technologies
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase I Trial of an Investigational Small Pox Medication (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ST-246 Days 11 - 13 CI brief — competitive landscape report
ST-246 Days 11 - 13 updates RSS · CI watch RSS
SIGA Technologies portfolio CI